Storia in 2 fonti

Merck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 win

Merck's tulisokibart hits Phase 3 primary endpoint in ulcerative colitis, a first win for anti-TL1A drugs and the $10.8B Prometheus deal.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Merck's tulisokibart hits Phase 3 primary endpoint in ulcerative colitis, a first win for anti-TL1A drugs and the $10.8B Prometheus deal.

Merck reported positive Phase 3 data for tulisokibart in ulcerative colitis, meeting primary and key secondary endpoints.